Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 112,819 | 119,907 | 120,792 | 113,827 | 147,794 |
| Cost of Goods | 49,012 | 43,909 | 38,260 | 40,607 | 64,851 |
| Gross Profit | 63,807 | 75,998 | 82,532 | 73,220 | 82,943 |
| Operating Expenses | 74,870 | 82,008 | 81,948 | 70,157 | 81,179 |
| Operating Income | -11,051 | -5,101 | 844 | 3,670 | 2,615 |
| Other Income | 1,744 | 2,337 | 2,312 | 654 | -188 |
| Pre-tax Income | -9,307 | -2,764 | 3,156 | 4,324 | 2,427 |
| Income Tax | 672 | 6,064 | 6,595 | 2,124 | -1,707 |
| Net Income Continuous | -9,979 | -8,828 | -3,439 | 2,200 | 4,134 |
| Net Income Discontinuous | -901 | -47,557 | -79,228 | -17,059 | N/A |
| Net Income | $-10,880 | $-56,385 | $-82,667 | $-14,859 | $4,134 |
| EPS Basic Total Ops | -0.76 | -3.83 | -5.64 | -1.02 | 0.29 |
| EPS Basic Continuous Ops | -0.70 | -0.60 | -0.23 | 0.15 | 0.29 |
| EPS Basic Discontinuous Ops | -0.06 | -3.23 | -5.41 | -1.17 | N/A |
| EPS Diluted Total Ops | -0.76 | -3.83 | -5.64 | -1.02 | 0.28 |
| EPS Diluted Continuous Ops | -0.70 | -0.60 | -0.23 | 0.15 | 0.28 |
| EPS Diluted Discontinuous Ops | -0.06 | -3.23 | -5.41 | -1.17 | N/A |
| EPS Diluted Before Non-Recurring Items | -0.66 | -0.46 | -0.30 | -0.49 | -0.02 |
| EBITDA(a) | $-5,322 | $5,482 | $77,251 | $18,157 | $23,997 |